SCHEMBL366798

SCHEMBL366798

NC(=O)c1cccc([N+](=O)[O-])c1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.56
TSHR P16473 3/20 0.52
CTSD P07339 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TDP1 Q9NUW8 4/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PLAU P00749 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
PARP1 P09874 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8302538 0.98 GPR35 (0.55) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL782111 0.98 GPR35 (0.55) GPR35TSHRCTSDALDH1A1TDP1
Aziridine SCHEMBL3049817 0.92 GPR35 (0.49) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL782562 0.91 GPR35 (0.47) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL19127226 0.91 GPR35 (0.47) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL5792626 0.88 TSHR (0.48) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL30893562 0.85 TSHR (0.68) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL3671 0.85 TSHR (0.68) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL7417028 0.85 GPR35 (0.60) GPR35TSHRCTSDALDH1A1TDP1
SCHEMBL7263414 0.85 GPR35 (0.60) GPR35TSHRCTSDALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727950-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2026-04-22 EP claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
EP-4602052-A1 PROTEIN-BASED SIGNAL AMPLIFICATION California Institute of Technology (US) 2025-08-20 EP claimed
WO-2025096495-A1 ARYL FLUOROSULFATE-BASED INHIBITORS AS NOVEL ANTITUBERCULAR AGENTS THE SCRIPPS RESEARCH INSTITUTE (US) 2025-05-08 WO claimed
US-20250129084-A1 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-04-24 US claimed
EP-4486454-A1 COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-01-08 EP claimed
WO-2024256554-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-12-19 WO claimed
US-20240307385-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-19 US claimed
US-20240269340-A1 MICROSPHERES WITH FLOW THROUGH VOIDS AS EMBOLIC AND DRUG DELIVERY AGENTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2024-08-15 US claimed
EP-4388114-A1 CELL-TO-CELL DELIVERY OF RNA CIRCUITS California Institute of Technology (US) 2024-06-26 EP claimed
EP-0934068-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-08-11 EP claimed
WO-1998009630-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1998-03-12 WO claimed
CN-1151695-A pharmaceutical composition containing benzamide CENTAUR PHARMACEUTICALS INC (US) 1997-06-11 CN claimed
EP-0091383-B1 PROCESS FOR THE CATALYTIC REDUCTION OF NITRO-AROMATIC COMPOUNDS Montedison S.p.A. (IT) 1987-03-04 EP claimed
EP-0097592-B1 PROCESS FOR CATALYTICALLY REDUCING NITROAROMATIC COMPOUNDS Montedison S.p.A. (IT) 1986-12-10 EP claimed
US-4535162-A USING GROUP 8 METAL COORDINATION CATALYSTS MONTEDISON S.P.A. (IT) 1985-08-13 US claimed
EP-0097592-A2 Process for catalytically reducing nitroaromatic compounds Montedison S.p.A. (IT) 1984-01-04 EP claimed
EP-0091383-A1 Process for the catalytic reduction of nitro-aromatic compounds Montedison S.p.A. (IT) 1983-10-12 EP claimed
US-4260540-A SPIN DYEING POLYACRYLONITRILE BAYER AKTIENGESELLSCHAFT (DE) 1981-04-07 US claimed
US-4225489-A Heterocyclic azo dyes and pigments containing 4-quinazolinone moieties BAYER AKTIENGESELLSCHAFT (DE) 1980-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129084-A1 Compounds CFTR, TBCA, TBCD GPR35 2651/4885TSHR 3455/4885CTSD 755/4885
US-20240307385-A1 NOVEL COMPOUNDS FNTB, SDHA, FDPS GPR35 2177/4885TSHR 3330/4885CTSD 1624/4885
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 GPR35 2067/4885TSHR 620/4885CTSD 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.